Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid and Bone Markers in Prostate Cancer
NCT00172055Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2004
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zoledronic acid in cancer treatment-induced bone loss (CTIBL), sponsored by Novartis. Primary endpoint: C-terminal telopeptide of type I collagen at 6 months. Started Dec 2004; status: completed.
02
Drugs
zoledronic acid
03
Conditions
cancer treatment-induced bone loss (CTIBL)
Beyond the preview
Go deeper on NCT00172055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00172055.